INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
468.35 EUR
+7.55 (+1.64%)
Taking everything into account, IUI1 scores 6 out of 10 in our fundamental rating. IUI1 was compared to 68 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 is valued quite expensive, but it does show an excellent growth. This makes IUI1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year IUI1 was profitable.
- IUI1 had a positive operating cash flow in the past year.
- In the past 5 years IUI1 has always been profitable.
- In the past 5 years IUI1 always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 14.19%, IUI1 belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
- With an excellent Return On Equity value of 16.12%, IUI1 belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
- The Return On Invested Capital of IUI1 (11.69%) is better than 82.35% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 9.73%.
- The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(11.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
- The Profit Margin of IUI1 (28.58%) is better than 95.59% of its industry peers.
- IUI1's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 29.44%, IUI1 belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
- In the last couple of years the Operating Margin of IUI1 has declined.
- The Gross Margin of IUI1 (66.38%) is better than 73.53% of its industry peers.
- IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
- The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
- IUI1 has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.18
WACC9.88%
2.3 Liquidity
- IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 4.97, IUI1 belongs to the best of the industry, outperforming 95.59% of the companies in the same industry.
- A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 4.20, IUI1 belongs to the best of the industry, outperforming 95.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 28.12% over the past year.
- Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
- Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
- The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
- The Earnings Per Share is expected to grow by 15.67% on average over the next years. This is quite good.
- IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.12% yearly.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 63.21, which means the current valuation is very expensive for IUI1.
- IUI1's Price/Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 61.76% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.54. IUI1 is valued rather expensively when compared to this.
- IUI1 is valuated quite expensively with a Price/Forward Earnings ratio of 54.86.
- 73.53% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
- IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.21 | ||
| Fwd PE | 54.86 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 69.12% of the companies in the same industry.
- IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 84.97 | ||
| EV/EBITDA | 53.51 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of IUI1 may justify a higher PE ratio.
- A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)3.14
PEG (5Y)5.5
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
- No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/15/2026, 7:00:00 PM)
468.35
+7.55 (+1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-21 2025-10-21/amc
Earnings (Next)01-22 2026-01-22/amc
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap166.03B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target523.6 (11.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)-0.15%
PT rev (3m)2.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.15%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.21 | ||
| Fwd PE | 54.86 | ||
| P/S | 20.08 | ||
| P/FCF | 84.97 | ||
| P/OCF | 65.19 | ||
| P/B | 11.32 | ||
| P/tB | 11.56 | ||
| EV/EBITDA | 53.51 |
EPS(TTM)7.41
EY1.58%
EPS(NY)8.54
Fwd EY1.82%
FCF(TTM)5.51
FCFY1.18%
OCF(TTM)7.18
OCFY1.53%
SpS23.33
BVpS41.36
TBVpS40.51
PEG (NY)3.14
PEG (5Y)5.5
Graham Number83.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC9.88%
ROIC/WACC1.18
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.